 |
|
No Increase in Risk of Myocardial Infarction to Postmenopausal Women Receiving Combined Estrogen-Progestin TherapyThe Risk of Myocardial Infarction Associated With the Combined Use of Estrogens and Progestins in Postmenopausal Women
B. M. Psaty, MD, PhD;
S. R. Heckbert, MD, PhD;
D. Atkins, MD, MPH;
R. Lemaitre, PhD;
T. D. Koepsell, MD, MPH;
P. W. Wahl, PhD;
D. S. Siscovick, MD, MPH;
E. H. Wagner, MD, MPH
Arch Fam Med. 1995;4(12):59-60.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings. |
|
|
|
Purpose of Study:
To investigate whether combined therapy with estrogen and progestins adversely affects the risk of myocardial infarction (MI) in postmenopausal women. The underlying rationale of this question is twofold. First, unopposed estrogen, previously used in postmenopausal hormonereplacement therapy, is known to reduce the risk of MI in these patients. Second, while beneficial in minimizing the risk of endometrial hyperplasia and uterine cancer posed by estrogen alone, the addition of progestins has been shown to adversely affect serum lipid levels, which in turn negatively affect the risk of MI.
Materials & Methods:
An epidemiologic case-control study of 502 postmenopausal women with a history of a fatal or nonfatal MI episode occurring in 1986 through 1990 was carried out among the enrollees of a health maintenance organization. Controls were a stratified random sample of
. . . [Full Text PDF of this Article]
|
